Treatment for Marburg Virus Disease using Monoclonal Antibodies
Official title: Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease
Funded at Abvacc, INC. · NIH-11261287 · Data updated 2026-11-12
This study is testing a new treatment made from special antibodies to help people with Marburg Virus Disease, aiming to make it safer and more effective for those who are affected by this serious illness.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 11, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 4R44AI179371-02 |
| Project ID | NIH-11261287 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals diagnosed with Marburg Virus Disease or those at high risk of exposure to the virus.
✕Less likely to help
Patients with other viral infections or those not affected by Marburg Virus Disease are unlikely to benefit from this research.
What this research studies
This research focuses on developing a monoclonal antibody cocktail specifically designed to treat Marburg Virus Disease, which is known for its high fatality rates. The approach involves creating antibodies that target different parts of the virus to enhance treatment efficacy. By utilizing advanced techniques to improve the antibodies' effectiveness and bioavailability, the research aims to provide a robust therapeutic option for patients affected by this severe viral infection. The study will involve both laboratory and clinical evaluations to ensure safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could provide a life-saving treatment option for patients suffering from Marburg Virus Disease.
How similar studies have gone: Previous research on monoclonal antibody therapies for similar viral diseases, such as Ebola, has shown promising results, indicating a potential for success in this novel approach.
Where this research is happening
-
Abvacc, INC.
Rockville, United States Active
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.